1	Antimicrobial resistance patterns of bacterial isolates from bloodstream
2	infections at Jinja regional referral hospital: A cross-sectional study
3	
4	Fahad Lwigale ^{1,2*}
5	
6	¹ Global Health Security Program, Infectious Diseases Institute, College of Health Sciences,
7	Makerere University, Kampala, Uganda;
8	
9	² Jinja Regional Referral Hospital, Jinja, Uganda
10	
11	*Corresponding author
12	Email:fahadlwigale@gmail.com (FL), flwigale@idi.co.ug (FL)
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract:

Introduction

Bloodstream infections are a commonly encountered clinical syndrome of public health concern with variable epidemiology. The characteristic of resistance to multiple antibiotics by their etiologic agents has limited the options for empirical sepsis case management. This study determined the most frequent aetiologic agents responsible for bloodstream infections, their antimicrobial susceptibility patterns, and infection sources in Eastern-Central Uganda.

30

31

32

33

34

35

36

37

29

23

24

25

26

27

28

Materials and methods

This retrospective study involved analysis of all non-duplicate blood culture reports from 2019 to 2021. The frequency and percentage of significant pathogenic organisms and contaminants were calculated. Positivity distribution including infection sources was determined. World Health Organization Network (WHONET) 2022 desktop software was used for antimicrobial susceptibility data analysis.

Results

The 1364 participants had a diagnostic yield of 114(6.8%) and a 1.5% contamination rate. 38 Over 37% and 13% of infections were hospital and community-acquired respectively. Most 39 etiologic agents were Gram-positive bacteria dominated by Staphylococcus aureus 39(34.2%). 40 Gram-negatives mainly included unspecified Coliforms 12(10.5%), and E. coli 10(8.8%). 41 Polymicrobial growth existed in 4(0.3%) cases. S. aureus was mainly resistant to Penicillin G 42 (100%), Cefoxitin (60%), and Erythromycin (52.2%). Both Escherichia coli and unspecified 43 coliforms showed high resistance to Ampicillin (87.5%) and third-generation Cephalosporins 44 (100%). The least resistance was to Chloramphenicol and Carbapenems. 45

Conclusion

46

47

48

49

50

51

52

BSIs are mainly due to Gram-positive bacteria. Suspected sepsis cases by *S. aureus* in this region can be empirically managed using Gentamicin. Microbiology services should be routinely utilized to guide antimicrobial use, monitor blood culture contamination rates and resistance trends to strengthen regional antimicrobial stewardship.

Introduction

Bloodstream Infections (BSIs) are some of the most commonly encountered and serious 53 Healthcare-Associated Infections (HAIs) of public health concern(1-3). This results from 54 microorganisms accessing the bloodstream where they reproduce and excrete toxins during 55 septicemia (4). It is characterized by a number of symptoms including fever (>38°C), chills, 56 hypotension, tachypnea, hypothermia (<36°C), apnea, or bradycardia depending on different 57 factors including the age group (2, 5). A Bloodstream Infection (BSI) is confirmed by a 58 positive blood culture in the microbiology laboratory whether primary or secondary (1, 2, 6). 59 A primary BSI is a laboratory-confirmed positive blood culture without any link to another 60 infected body site (5). A secondary BSI on the other hand involves the isolation of an 61 organism within a 14-17-day period from the bloodstream with the same identity as one 62 responsible for another existing body site-specific infection or contributes to a syndrome (5). 63 This can be a urinary tract infection (UTI), respiratory tract infection (RTI), or skin and soft 64 tissue infection (SSTI) among others. 65

Among all ages, BSIs are one of the major causes of morbidity and mortality in both developed and developing countries (7, 8). In the United States of America (USA), they are the 11th leading cause of mortality and among the top seven causes of death in Europe (9). Among febrile neutropenic patients, 6% of deaths are due to BSIs (10). They cause 13-15%

of deaths in case of neonatal sepsis and 30-50% of deaths in developing countries (7). The 70 mortality rate is 33.3% -46.9% in Italy (2). Among cancer patients, BSIs are responsible for 71 a death rate of 24% and 33% in developed and then low- and middle-income countries (LMIC) 72 respectively (11). As an emergency condition, sepsis requires immediate detection and 73 identification of the causative agent for proper treatment in the current era of the 74 Antimicrobial Resistance (AMR) silent pandemic(1, 12). For this matter, blood culture testing 75 is an important tool for the diagnosis of BSIs and AMR surveillance at large(4, 6, 13). 76 Pathogen Recovery from the blood cultures has been observed to vary in Asia and Africa with 77 comparable levels ranging from 6.11% to 27.1% (3, 10, 14-16). It was as high as 71% in 78 Ethiopia (17). East African levels are 11.71% to 14.2% (18, 19). Uganda has previously been 79 reported to have a diagnostic yield of 4.6% with 2.6% for Jinja (13). However, up to 14.1% 80 positivity has been observed among cancer patients (11). The majority of studies unanimously 81 report males to be the major victims of the BSIs ranging from 60.4% to 65% (2, 4, 9, 20). The 82 majority belonged to 18-88 years of age (9, 20). BSIs of hospital origin have been reported to 83 range between 10% to 81.5% (2, 4, 8). Community-acquired BSIs have also been reported to 84 be as high as 91.1% to 91.6% elsewhere(14, 21). 85 Geographic and epidemiological factors have resulted in differences in the profile of BSIs 86 observed(2, 8, 9, 11, 12). Gram-negative organisms have been reported to be dominant in 87 some areas (11, 12, 15, 19, 22). ESKAPE composed of *Enterococcus faecium*, *Staphylococcus* 88 aureus, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 89

aeruginosa, and *Enterobacter species* altogether contributes up to 70% of the observed BSIs (23). This is dominated by *E. coli*, *K. pneumoniae*, *S. epidermidis*, and *S. aureus* (23). Many others are similar to that (9, 12). Other studies indicate Gram-positive bacteria especially *Staphylococcus species* and *Enterococcus species* to be of a higher frequency(3, 4, 17, 20). AMR priority pathogens including *Staphylococcus aureus* (54%), *Escherichia coli* (19%),

90

91

92

93

Salmonella species (11%), Streptococcus pneumoniae, and Klebsiella species (5%) were
 previously reported as the most dominant in Uganda (13).

Variably high resistance levels have been reported for multiple antibiotics including 97 Gentamicin, Cephalosporins, and Carbapenems among Enterobacterales and Acinetobacter 98 baumannii (9, 11, 18). There is an exhibition of different resistance phenotypes with levels 99 up to 28.9% of Methicillin-Resistant S. aureus (MRSA), 23.9% of Extended-spectrum beta-100 lactamase (ESBL) producers while the Carbapenem-resistant (CarbR) are up to 26.3% (2). In 101 Uganda, up to 57.1% resistance to Imipenem is reported (11). The majority of isolates have 102 been observed to be more susceptible to Meropenem, Amikacin, Piperacillin/Tazobactam, 103 and Ciprofloxacin (9, 12, 17, 24). These infections are commonly empirically managed using 104 a combination of broad-spectrum intravenously administered antibiotics such as Ceftriaxone 105 and Metronidazole. However, empirical therapy has been reported to facilitate the emergence 106 of Antimicrobial resistance(7, 25). In this case, microorganisms can thrive in an environment 107 composed of an antimicrobial agent previously capable of killing it or preventing its 108 reproduction. Bacterial isolates of this nature have been associated with bloodstream 109 infections (BSIs) where they exhibit Multi-Drug Resistant (MDR) phenotypes such as the 110 Methicillin Resistant Staphylococcus aureus (MRSA), Extended Spectrum Beta Lactamase 111 (ESBL) producers and Carbapenem-resistant (CarbR) organisms (2, 7, 18). This increases the 112 possibility of therapy failure, longer hospital-stay periods with increased risk of acquisition 113 of more infections, high healthcare costs, and a higher risk of death (9, 10, 25). 114

Despite the setup of the Medicines and Therapeutic Committee (MTC) and the Infection Prevention and Control (IPC) committees at Jinja regional referral hospital (Jinja RRH) by the ministry of health (MoH) of Uganda and implementing partners such as the Infectious Diseases Institute (IDI), there is a shortage of congregated up-to-date information to guide the choice of antibiotics for empirical therapy to ensure better control of antimicrobial use and

consumption in the region served by the facility. This is in addition to a shortage in 120 microbiology services as this site is the only supplier in the region and yet it is also affected 121 by other factors including a shortage of supplies and staff resulting in intermittent availability 122 of information for targeted therapy of bloodstream infections. The ever-changing 123 microbiological profile of BSIs and the lack of published literature about this region makes it 124 necessary to routinely generate, analyze and utilize the local data about infectious syndromes. 125 This study aimed at determining the levels and distribution of the main causative agents for 126 BSIs at Jinja RRH, their antibiotic profiles and major sources of the infections. This was well 127 achieved. It will in turn help physicians, MTC, IPC committees, and policymakers to 128 formulate guidelines for the management of BSIs, better infection prevention and control, and 129 improve the antimicrobial stewardship and surveillance activities in Jinja RRH and the 130 Eastern-Central region of Uganda. 131

132

133

135

136

137

Materials and methods

134 Operatio

Operational definition

A Bloodstream Infection (BSI) refers to a positive blood culture test due to isolation of a significant pathogenic microorganism/s from the suspected patient's blood sample. The organism can be bacterial or fungal in nature.

138

139

Study design, setting, and population

This was a retrospective cross-sectional study conducted in 2022 using data generated over a two-and-a-half-year period from January 2019 through June 2021. This period was shortly after the stabilization of microbiology service delivery in the region. The Corona Virus Disease-2019 (COVID-19) pandemic was experienced in the same time zone and significantly

impacted health service delivery. The data was collected at Jinja regional referral hospital.
This is a 500-bed capacity hospital located along Bax Street within the central town of Jinja
city in the Eastern-Central part of Uganda. As a referral hospital, this facility serves a
population of approximately 4.5 million people from within Jinja and the surrounding areas
of over 11 districts including Iganga, Mayuge, Kamuli, Buikwe, Lugazi, Kayunga, and
Mukono districts.

The facility is equipped with a microbiology laboratory where examinations of various 150 samples are conducted for routine patient care and management. Blood culture was carried 151 out using the BD-BACTEC™ FX40 (BacT/ALERT) automated system. Organism 152 identification was carried out using conventional methods up to the genus and species levels. 153 Antimicrobial susceptibility testing was carried out using the Kirby-Bauer disk diffusion 154 method following the Clinical and Laboratory Standards Institute (CLSI) guidelines; CLSI-155 2018-M100-S28(26), CLSI-2020-M100-S30(27) and CLSI-2021-M100-S31 (28). There 156 were different antibiotic categories tested as commonly used against different organisms. The 157 Penicillins included Penicillin G (10 units), Ampicillin(10ug), and Piperacillin (100ug). 158 Cephalosporins included Ceftriaxone (30µg), Cefotaxime (30µg), Cefuroxime(30µg), 159 Ceftazidime(30µg) and Cefoxitin (30µg). Combinations included Amoxicillin/Clavulanate 160 $(20/10)\mu g$ Trimethoprim/Sulfamethoxazole(Co-trimoxazole) (1.25/23.75)µg. and 161 Erythromycin(15ug) was tested among the Macrolides. Carbapenems involved Imipenem 162 (10µg), Meropenem (10µg) and Ertapenem (10µg). Fluoroquinolones mainly included 163 Ciprofloxacin(5µg). The Lincosamide tested was Clindamycin (2µg). Aminoglycosides 164 included Gentamicin (10µg) and Amikacin (30µg). Tetracycline and Chloramphenicol of 165 composition 30µg each were also included. 166

167 This study aimed to determe the level of bloodstream infections and their common etiological 168 agents; the percentage resistance and/or sensitivity of the etiological agents to common

antibiotics; and the levels of community and healthcare-associated infections. A sample size of 410 participants was estimated using a 5% prevalence and a precision of 0.021 at 95% confidence. However, data from all patients (1364) with suspected BSI and non-duplicate blood culture tests carried out during the study period was considered. The higher sample size was aimed at increasing the chances of obtaining the minimum of thirty (30) isolates necessary to generate reliable cumulative antibiograms according to CLSI-M39A4E-2014 (29).This together was to increase precision and have a better representation of the population.

176

177

Data Management

The data necessary for the study was accessed in 2022 and extracted from the African 178 Laboratory Information System (ALIS) into an excel sheet. This was cleaned and anonymized 179 by removal specific identifiers such as patient names and numbers before being analyzed. All 180 sex types and age groups such as pediatrics, adolescents, and adults were included in the 181 analysis. Only the first isolate of every patient in the study time period was included in the 182 analysis to generate the antimicrobial susceptibility patterns as guided by CLSI-M39A4E-183 2014 (29). Organisms commonly found on the skin such as Coagulase negative 184staphylococcus(CoNS), Corynebacterium Species, and Bacillus species other than B. 185 anthracis were treated as contaminants. The rest of the organisms were considered significant 186 aetiologic agents when calculating the frequencies and respective percentages. 187

Hospital and community-acquired infections were defined based on the duration of patient hospitalization at the facility before sample collection. The infections diagnosed among personnel admitted and exposed to the hospital premises for at least 48 hours (two days) were treated as healthcare-associated (Hospital-acquired/Nosocomial) infections. Communityacquired infections on the other hand involved personnel exposed to the premises of the hospital for less than 48 hours. Respective frequencies and percentages were calculated.

194

195 Ethics Statement

The Jinja Hospital Research and Ethics Committee approved the study with registration number **JREC 159/2022.** The data was obtained from records of personnel who seek medical services at the facility. This is kept in medical records including patients files, laboratory request forms and information systems for proper care and later reference. The Microbiology Laboratory records were anonymously analyzed for this study and no consent was obtained from individual personnel.

202

203

204 205

Statistical analysis

Microsoft Excel (2016) was used for data cleaning and descriptive analysis. World Health 206 Organization Network (WHO-NET 2022) desktop software was used to analyze the 207 antimicrobial susceptibility data. Only the first isolate of every participant was involved in 208 generation of antimicrobial susceptibility profiles. These were presented as percentage 209 resistance and/or sensitivity/susceptibility. Results including positivity distributions, 210 hospitalization history, organisms/aetiologic agents and AST data were presented in the form 211 of frequencies and percentages in different tables and figures. There was a description of their 212 distribution in socio-demographics including age, sex, and location (wards). 213

214

215

216

217

Results

Growth

219

220	A total of 1364 participants were involved in the analysis. 800(58.7%) were male while
221	females were 564(41.3%). The majority (86.2%) of participants were less than 12 years of
222	age. A total of 114(8.4%) blood samples were positive. Of these, 93 had significant growth
223	representing a true diagnostic yield of 6.8% as shown in Fig 1.
224	
225	
226	Fig 1. Levels of positivity for blood cultures. The observed prevalence of bloodstream
227	infections is 6.8%.
228	
229	The contamination rate observed was 1.5%. (Refer to Table 1 for details). Positivity was
230	observed more among the males 67(58.8%) than the females 47(41.2%) (Table 1). The
231	frequency and percentage of isolated organisms are illustrated in Fig 2. Of the 114 positive
232	cases, 68(60.0%) were Gram-positive bacteria while 44(38.6%) were Gram-negative.
233	Candida species represented the remainder.
234	
235	
236	Fig 2. Frequency and Percentage of Isolated Organisms.
237	
238	
239	Table 1. Positivity distribution in the different population groups.

Frequency	n	93	21	1250	1364
Percentage	%	6.8	1.5	91.6	100

Contaminant

NBG

Significant

Total

medRxiv preprint doi: https://doi.org/10.1101/2023.08.09.23293917; this version posted August 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . **Gram Reaction** Positive 49(70) 21(30) N/A 70 n(%) Negative 44(100)0(0)N/A 44 Sex n(%) Male 54(6.8) 13(1.6) 733(91.6) 800 517(91.7) Female 39(6.9) 8(1.4) 564

18(1.5)

0(0)

0(0)

2(3.8)

1(3.2)

0(0)

0(0)

18(1.6)

2(3.9)

0(0)

1(0.9)

1080(91.8)

40(90.9)

58(96.7)

46(86.8)

26(83.9)

22(95.7)

36(92.3)

1043(91.8)

46(90.2)

8(100)

95(88.8)

1176

44

60

53

31

23

39

1136

51

8

107

Total93(6.8)21(1.5)1250(91.6)1364A&E, Accidents and Emergency; ICU, Intensive Care Unit; NBG, No Bacterial Growth; N/A, NotApplicable; OPD, Outpatient Department

242

240

241

Age Group n(%)

Ward n(%)

≤12

13-18

19-35

36-59

 ≥ 60

OPD

A&E

Pediatric

Medical

ICU

Others

78(6.6)

4(9.1)

2(3.3)

5(9.4)

4(12.9)

1(4.3)

3(7.7)

75(6.6)

3(5.9)

0(0)

11(10.3)

- 243

Gram positive bacteria majorly included, *Staphylococcus aureus* 39(34.2%), *Coagulase negative staphylococcus* 20(17.5%) then *Streptococcus species* 7(6.1%). Gram-negative bacteria on the other hand were made of general unspecified *Coliforms* 12(10.5%), *E. coli* 10(8.8%), *Klebsiella species* 5(4.4%), *Acinetobacter species* 4(3.5%), *Pseudomonas aeruginosa* 3(2.6%), then *Salmonella species* 2(1.8%). Other organisms included *Candida albicans*, *Enterobacter*, *Serratia*, *Citrobacter*, and *Shigella species*. Most cases were observed in the pediatric unit among children less than 13 years of age. Polymicrobial growth was

observed in 4(0.3%) cases of which two involved a *Serratia species* and one had a *Bacillus species* in addition to the co-isolates.

253 254

251

252

255	Percentage resistance among S. aureus isolates is shown in Fig 3. Among E. coli and
256	unspecified <i>coliform</i> isolates combined(n=22), Percentage resistance to Ampicillin,
257	Cefuroxime, Ceftazidime, Cefotaxime, Gentamicin, Ciprofloxacin, Imipenem, Ertapenem,
258	Co-trimoxazole, Tetracycline, and Chloramphenicol was 87.5%, 100%, 100%, 100%, 50%,
259	50%, 20%, 33.3%, 66.7%,60%, and 28.6% respectively. Non-Enterobacterales (P.
260	aeruginosa and A. baumannii) together(n=7) had the following resistance profile;
261	Ceftazidime (20%), Aztreonam (50%), Imipenem (0%), Meropenem (50%), Gentamicin
262	(40%), Ciprofloxacin (33.3%) and Tetracycline (0%).

263

264

Fig 3: Percentage resistance for Staphylococcus aureus to common antibiotics.

265

266

267

268

269

270

Table 2 shows the total number of different isolates and respective proportions tested against the antibiotics. Further, respective frequencies for the Resistant(R), Intermediate(I), and Susceptible(S) categories as outcomes of the antimicrobial susceptibility test (AST) reporting format have been revealed. This details the ratio of organism to antibiotic tested with respective outcomes compared with the number of organisms isolated.

Table 2. Frequency and percentage of organisms tested against different antibiotics

										Nam	e of O	rganisn	1						
Antibiotic	AST	S. a	ureus	Str	epto	Colif	orms	E.	coli	Kleb	siella	Acine	tobacter	P. aer	uginosa	Salm	onella	Oth	ers
	Result	n =3	39	coc	cus	(Unsj	pecified)	n =	-10	Spec	ies	Specie	S	n =3		& Sh	igella	n =	11
				Species n =7		n =12				n =5		n =4				Speci n =3	es		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	% a	n	%
	R	-	-	-	-	2	16	5	50	3	60	-	-	-	-	2	60	-	-
Ampicillin	Ι	-	-	-	-	0	0	0	0	0	0	-	-	-	-	0	0	-	-
	S	-	-	-	-	1	8	0	0	0	0	-	-	-	-	0	0	-	-
	R	6	15	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Penicillin G	Ι	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	S	0	0	1	14	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	R	-	-	-	-	-	-	1	10	1	10	-	-	-	-	-	-	-	-
Piperacillin	Ι	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-
	S	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-
	R	3	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Cefoxitin	Ι	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	S	2	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	R	-	-	-	-	-	-	2	20	-	-	-	-	-	-	-	-	1	9
Cefuroxime	Ι	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	0	0
	S	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	0	0
	R	-	-	-	-	-	-	4	40	1	20	-	-	0	0	-	-	2	18
Ceftazidime	Ι	-	-	-	-	-	-	0	0	0	0	1	25	0	0	-	-	0	0
	S	-	-	-	-	-	-	0	0	0	0	0	0	2	60	-	-	0	0
	R	-	-	-	-	2	16	2	20	1	20	-	-	-	-	1	30	-	-
Cefotaxime	Ι	-	-	-	-	0	0	0	0	0	0	-	-	-	-	0	0	-	-
	S	-	-	-	-	0	0	0	0	0	0	-	-	-	-	0	0	-	-
	R	-	-	-	-	-	-	2	20	2	40	-	-	-	-	-	-	1	9
Ceftriaxone	Ι	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	0	0
	S	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	0	0
	R	4	10	0	0	3	25	3	30	2	40	0	0	2	60	-	-	1	9
Gentamicin	Ι	3	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	9
	S	20	51	1	14	2	16	4	40	2	40	2	50	1	30	-	-	3	27

	R	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-
Amikacin	Ι	_	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-
	S	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-
	R	6	15	0	0	6	50	3	30	2	40	2	50	0	0	0	0	2	18
Ciprofloxacin	Ι	7	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	27
	S	16	41	1	14	3	25	6	60	3	60	1	25	3	100	3	100	1	9
	R	12	31	4	57	-	-	-	-	-	-	-	-	-	-	-	-	1	9
Erythromycin	Ι	2	5	1	14	-	-	-	-	-	-	-	-	-	-	-	-	0	0
	S	9	23	2	57	-	-	-	-	-	-	-	-	-	-	-	-	0	0
	R	-	-	-	-	-	-	-	-	-	-	0	0	2	60	-	-	-	-
Meropenem	Ι	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-
	S	-	-	-	-	-	-	-	-	-	-	1	25	1	30	-	-	-	-
	R	-	-	-	-	2	16	0	0	0	0	0	0	-	-	-	-	0	0
Imipenem	Ι	-	-	-	-	1	8	0	0	0	0	0	0	-	-	-	-	0	0
	S	-	-	-	-	2	16	4	40	4	80	1	25	-	-	-	-	2	18
	R	-	-	-	-	1	8	0	0	0	0	-	-	-	-	1	30	0	0
Etarpenem	Ι	-	-	-	-	0	0	0	0	0	0	-	-	-	-	0	0	0	0

	S	-	-	-	-	0	0	2	20	1	20	-	-	-	-	0	0	1	9
	R	5	13	0	0	2	16	1	10	1	20	0	0	-	-	1	30	1	9
Tetracycline	Ι	4	10	1	14	1	8	0	0	0	0	0	0	-	-	0	0	0	0
	S	11	28	1	14	1	8	0	0	0	0	2	50	-	-	0	0	0	0
	R	3	8	2	28	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Clindamycin	Ι	2	5	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	S	17	44	1	14	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	R	2	5	0	0	1	8	1	10	3	60	-	-	-	-	-	-	3	27
hloramphenicol	Ι	0	0	1	14	0	0	0	0	0	0	-	-	-	-	-	-	0	0
	S	4	10	1	14	1	8	4	40	0	0	-	-	_	-	-	-	1	9
	R	-	-	-	-	0	0	2	20	2	40	-	-	-	-	0	0	2	18
Co-trimoxazole	Ι	-	-	-	-	0	0	0	0	0	0	-	-	-	-	0	0	0	0
	S	-	-	-	-	1	8	0	0	0	0	-	-	-	-	1	30	1	9
	R	-	-	0	0	-	-	-	-	-	-	-	-	_	-	-	-	0	0
Vancomycin	Ι	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	0	0
	S	-	-	5	71	-	-	-	-	-	-	-	-	-	-	-	-	1	9
	R	-	-	-	-	-	-	-	-	1	20	-	-	1	30	-	-	1	9

Aztrec	onam	Ι	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	0	0
		S	-	_	-	-	_	-	_	-	0	0	-	-	0	0	-	-	0	0
272	AST, Antir	nicrobia	l Suscej	ptibilit	y Tes	t; I, Ir	ntermed	liate; R,	, Resist	ant; S	S, Susc	eptible	;							
273	^a Percentage	es were o	calculate	ed for	isolat	es test	ted rela	tive to t	the nun	nber o	of isola	ted org	ganisms							
274																				
275																				
276																				
277																				
278																				
279																				
280																				
281																				
282																				
283																				
284																				
285																				
286																				
287																				

288

289	Table 3 shows the possible sources of infection in the different population groups for positive
290	cultures. Altogether, 36.8% and 13.2% of the positive cases were hospital-acquired and
291	community-acquired infections respectively. On a sad note, over 50% of the cases were of
292	unknown origin.

293

Table 3. Likely infection source in the different population groups for positive cultures.

		Possible Source of Infection									
		Hospi	tal	Comn	nunity	Unknown					
		n	%	n	%	n	%				
Overall		42	36.84	15	13.16	57	50.00				
Sex	Male	25	37.3	9	13.4	33	49.3				
	Female	17	36.2	6	12.8	24	51.1				
Age Group	<12	36	37.5	10	10.4	50	52.1				
	13-18	0	0.0	2	50.0	2	50.0				
	19-35	1	50.0	1	50.0	0	0.0				
	36-59	2	28.6	2	28.6	3	42.9				
	>60	3	60.0	0	0.0	2	40.0				
Ward	OPD	0	0.0	1	100.0	0	0.0				
	A&E	1	33.3	1	33.3	1	33.3				
	Pediatrics	35	37.6	9	9.7	49	52.7				
	Medical	3	60.0	1	20.0	1	20.0				
	ICU	0	0.0	0	0.0	0	0.0				
	Others	3	25.0	3	25.0	6	50.0				

A&E, Accidents and Emergency; ICU, Intensive Care Unit; NBG, No Bacterial Growth; OPD, Outpatient Department

Discussion

295

296

297

The BSIs are known life-threatening conditions with variable levels distributed. These are 298 diagnosed when at least a single blood culture is carried out and a pathogenic microorganism 299 is isolated. This study obtained a significant positivity level of 6.8%. This is greater than 4.6% 300 and 2.6% for Uganda and Jinja respectively as earlier observed (13). This indicates an 301 improvement in pathogen recovery from blood cultures. Similar levels have been obtained in 302 other studies (14-16, 18). Variations of prevalence in different units have also been reported 303 focusing on different facilities (3). Other previous studies obtained a relatively higher 304 prevalence of up to 71% (17). This could be due to the study population of cancer patients 305 majority of whom were neutropenic and hence at a higher risk for the BSIs (17, 30). 306

The highest prevalence of positivity was observed among the pediatrics. This could be 307 explained by the low immune status of the children making them more vulnerable to the BSIs. 308 Also, the largest number of samples were from children. This calls for the need to improve 309 the infection prevention measures in these units. Routine blood culture is also recommended 310 among adults fitting the definition to contribute more data about adults regarding BSIs. Up to 311 91.6% of the blood cultures had no bacterial growth. This could be due to the prior use of 312 antibiotics between 1-28 days before blood culture testing as observed in many participants, 313 especially in the period starting from early 2020. 314

More males (58.8%) were observed to have the BSIs and this is in agreement with the majority of previous studies(2, 4, 9, 20). Being male had also been associated with a high probability of having a BSI (crude OR 2.8, 95% CI 0.69–6.5; P=0.042) (17).

Gram-positive bacteria (61.4%) were found to be more dominant compared to their Gramnegative counterparts (38.6%). Previous studies obtained similar results (3, 4, 13, 17, 20).

Some research elsewhere also had differing observations where Gram-negatives were more than Gram-positives (11, 12, 15, 18, 19, 22). More variability was also shown in the study conducted in different ICUs (3). This provides a relatively larger tip of the iceberg regarding the variation of dominant organism distribution which calls for local data analysis and utilization.

S. aureus (34.2%) was the overall most commonly isolated organism at this site. The outcome 325 was also observed elsewhere (4, 13, 17). Among Gram-negatives, it was majorly unspecified 326 Coliforms (10.5%) followed by E. coli (8.8%) then Klebsiella species (4.4%), and 327 Pseudomonas aeruginosa (2.6%). This is comparable to observations by other studies (12, 328 23, 31). CoNS were also more frequently isolated in the pediatric samples than Streptococcus 329 species representing a contamination rate of 1.5% (21/1364). This was less than 13.6% and 330 4.8% observed at Princess Marina Hospital (PMH) and Tygerberg Hospital (TBH) neonatal 331 units in Sub-Saharan Africa (21). Other studies have also reported higher rates (2, 10, 11, 16, 332 20, 23). This could be due to the high likelihood of contamination in children's blood samples 333 during sample collection. However, the observed contamination rate falls within acceptable 334 limits ranging from 1-3% (6, 32). These isolates were not treated as true pathogens and no 335 AST was done on them. This is a good practise in order to avoid unnecessary use of antibiotics 336 in these children and their possible effects. On a sad note, only a single blood culture set was 337 commonly done for the different individuals. This is most likely due to the limited availability 338 of testing materials such as blood culture bottles among other factors. This limits the 339 capability to confirm the fact that common commensals could be responsible for some of the 340 true infections observed especially among immunocompromised individuals including 341 children. This in turn leaves them vulnerable to the BSIs of that origin. However, it is 342 recommended to employ appropriate policies to monitor and reduce the contamination levels 343 to less than 1% and enable avoidance of the associated consequences(32). 344

Antimicrobial Susceptibility Testing (AST) was variably done based on the availability of 345 testing materials. Each organism type was generally tested against at least 8 antibiotics except 346 for Pseudomonas aeruginosa and Acinetobacter species. However, the ratio of the individual 347 isolate to antibiotic tested was quite low (Refer to Table 2). This is similar to the observation 348 at Mulago hospital (33). This clearly shows the need for Uganda to improve in terms of supply 349 management and ensure the availability of necessary logistics for laboratory testing. For the 350 number of S. aureus isolates tested against Cefoxitin, 60% turned out resistant indicating a 351 possibility of high levels of MRSA in circulation. These (100%) being β -Lactamase producers, 352 they had already shown no response to Penicillin G. However, Gentamicin 74.1% (%S 95% 353 CI=53.4-88.1), Ciprofloxacin 55.2% (%S 95% CI=36.0-73.0), and Tetracycline 55% (%S 95% 354 CI=32.0-76.2) showed better activity against S. aureus compared to other agents. 355

E. coli and unspecified coliforms combined (n=22) showed relatively high levels of resistance 356 to commonly used antibiotics for empiric and targeted case management in the study setting 357 such as the third-generation Cephalosporins. They also showed 20% and 33.3% resistance to 358 Impenem and Ertapenem respectively among the tested isolates. This indicates a possibility 359 of increasing resistance to the reserved options limiting the availability of better alternatives 360 when faced with cases of MDR pathogens. A similar feature was observed among the Non-361 Enterobacterales although they were susceptible to Tetracycline. However, there were fewer 362 than 30 isolates for these two groups of organisms making it impossible to make appropriate 363 conclusions about their susceptibility patterns as guided by Clinical and Laboratory Standards 364 Institute (CLSI-M39A4E-2014) (29). 365

Data were scarce regarding the hospitalization of patients prior to sample collection. This was observed in over 50% of the data. However, based on the available information, at least 37% had their BSI being nosocomial. This is linked to the fact that they were exposed to the hospital environment for more than 48 hours before being sampled for testing. This increases

the likelihood that the infection was acquired from the hospital making it necessary to 370 strengthen IPC measures observed in the facility before it is too late. Similar observations 371 were made elsewhere (2). However, higher levels of the same kind have been reported among 372 non-ICU hospitalized patients (8). The remaining 13% of the positive cases can be linked to 373 community-acquired infections. It is less than what is reported by other studies but there is 374 room for more (14, 21). This calls for the need to improve information management at the 375 testing and surveillance sites to enable capturing of all necessary data about the cases managed. 376 Further study might also be needed to identify the possible causes of the data incompleteness 377 at the different surveillance sites. 378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

Conclusions

S. aureus is the most common organism responsible for bloodstream infections at this site. There is a relatively high level of resistance to commonly used antibiotics among all organisms. Currently, Gentamicin can be used to empirically manage suspected *S. aureus* BSIs in this region. It is recommended to routinely utilize microbiology services with proper data management to guide antimicrobial use and monitor blood culture contamination rates and antimicrobial resistance trends to strengthen antimicrobial stewardship and surveillance policies in the Eastern-Central region of Uganda.

Acknowledgments

The author appreciates all contribution from the administration and staff of Jinja Regional Referral Hospital, especially the Children's ward, Nalufenya for the great work together with Ms. Kasuswa Sophia, Mr. Kasibante Samuel, and Ms. Matinyi Sandra for the research

encouragement. The author thanks the Infectious Diseases Institute for the support to offer
 microbiology services at this site.

395 **References**

3961.Timsit J-F, Ruppé E, Barbier F, Tabah A, Bassetti M. Bloodstream infections in critically ill patients: an expert

397 statement. Intensive Care Medicine. 2020;46(2):266-84.


- 2. Santoro A, Franceschini E, Meschiari M, Menozzi M, Zona S, Venturelli C, et al. Epidemiology and Risk Factors
- 399 Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria.
- 400 Open Forum Infectious Diseases. 2020;7(11).
- 401 3. Duan N, Sun L, Huang C, Li H, Cheng B. Microbial Distribution and Antibiotic Susceptibility of Bloodstream
- 402 Infections in Different Intensive Care Units. Front Microbiol. 2021;12:792282.
- 403 4. Hussain MS, Basher H, Lone MS, Wani K. Bloodstream Infections in Pediatric Population in a Tertiary Care
 404 Hospital. 2019.
- 5. NHSN. Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line
 Associated Bloodstream Infection) 2023 [updated 2023, January. Available from:
 https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf
- 6. CLSI. Principles and Procedures for Blood Cultures; Aproved Guideline.CLSI document M47-A. Wayne, PA:
 Clinical and Laboratory Standards Institute. 2007:110.
- 410 7. Sarkar S, Bhattacharyya A, Paria K. A Retrospective Study on Bacteria Causing Blood Stream Infection: Antibiotics
- 411 Resistance and Management. Indian Journal of Pharmaceutical Sciences. 2018;80(3):547-51.
- Tian L, Zhang Z, Sun Z. Antimicrobial resistance trends in bloodstream infections at a large teaching hospital in
 China: a 20-year surveillance study (1998-2017). Antimicrobial resistance & infection control. 2019;8(1):1-8.
- Bandy A, Almaeen AH. Pathogenic spectrum of blood stream infections and resistance pattern in Gram-negative
 bacteria from Aljouf region of Saudi Arabia. PLOS ONE. 2020;15(6):e0233704.
- 416 10. Paul M, Bhatia M, Rekha US, Omar BJ, Gupta P. Microbiological Profile of Blood Stream Infections in Febrile
- 417 Neutropenic Patients at a Tertiary Care Teaching Hospital in Rishikesh, Uttarakhand. Journal of Laboratory Physicians.
 418 2020;12(02):147-53.
- 419 11. Lubwama M, Phipps W, Najjuka CF, Kajumbula H, Ddungu H, Kambugu JB, et al. Bacteremia in febrile cancer
- 420 patients in Uganda. BMC research notes. 2019;12(1):1-6.

421	12.	Zou Q, Zou H, Shen Y, Yu L, Zhou W, Sheng C, et al. Pathogenic Spectrum and Resistance Pattern of Bloodstream
422	Infectio	ns Isolated from Postpartum Women: A Multicenter Retrospective Study. Infection and drug resistance. 2021;14:2387
423	13.	Kisame R, Najjemba R, van Griensven J, Kitutu FE, Takarinda K, Thekkur P, et al. Blood culture testing outcomes
424	among	non-malarial febrile children at antimicrobial resistance surveillance sites in Uganda, 2017–2018. Tropical Medicine
425	and Inf	ectious Disease 2021:6(2):71


- Myat TO, Oo KM, Mone HK, Htike WW, Biswas A, Hannaway RF, et al. A prospective study of bloodstream
 infections among febrile adolescents and adults attending Yangon General Hospital, Yangon, Myanmar. PLoS neglected
 tropical diseases. 2020;14(4):e0008268.
- Marchello CS, Dale AP, Pisharody S, Rubach MP, Crump JA. A systematic review and meta-analysis of the
 prevalence of community-onset bloodstream infections among hospitalized patients in Africa and Asia. Antimicrobial
 agents and chemotherapy. 2019;64(1):e01974-19.
- 432 16. Ombelet S, Kpossou G, Kotchare C, Agbobli E, Sogbo F, Massou F, et al. Blood culture surveillance in a secondary
- care hospital in Benin: epidemiology of bloodstream infection pathogens and antimicrobial resistance. BMC infectious
 diseases. 2022;22(1):1-15.
- Arega B, Woldeamanuel Y, Adane K, Sherif AA, Asrat D. Microbial spectrum and drug-resistance profile of isolates
 causing bloodstream infections in febrile cancer patients at a referral hospital in Addis Ababa, Ethiopia. Infection and drug
 resistance. 2018;11:1511-9.
- 438 18. Seni J, Mwakyoma A, Mashuda F, Marando R, Ahmed M, DeVinney R, et al. Deciphering risk factors for blood
 439 stream infections, bacteria species and antimicrobial resistance profiles among children under five years of age in North440 Western Tanzania: a multicentre study in a cascade of referral health care system. BMC pediatrics. 2019;19(1):1-11.
- Habyarimana T, Murenzi D, Musoni E, Yadufashije C, N Niyonzima F. Bacteriological Profile and Antimicrobial
 Susceptibility Patterns of Bloodstream Infection at Kigali University Teaching Hospital. Infection and drug resistance.
 2021;14:699-707.
- 444 20. AbuTaha SA, Al-Kharraz T, Belkebir S, Abu Taha A, Zyoud SeH. Patterns of microbial resistance in bloodstream
 445 infections of hemodialysis patients: a cross-sectional study from Palestine. Scientific Reports. 2022;12(1):1-10.
- Gezmu AM, Bulabula ANH, Dramowski A, Bekker A, Aucamp M, Souda S, et al. Laboratory-confirmed
 bloodstream infections in two large neonatal units in sub-Saharan Africa. International Journal of Infectious Diseases.
 2021;103:201-7.

- Kokkayil P, Agarwal R, Mohapatra S, Bakshi S, Das B, Sood S, et al. Bacterial profile and antibiogram of blood
 stream infections in febrile neutropenic patients with haematological malignancies. The Journal of Infection in Developing
- 451 Countries. 2018;12(06):442-7.
- 452 23. Yang S, Xu H, Sun J, Sun S. Shifting trends and age distribution of ESKAPEEc resistance in bloodstream infection,
- 453 Southwest China, 2012–2017. Antimicrobial Resistance & Infection Control. 2019;8(1):1-10.
- 454 24. Semret M, Abebe W, Kong LY, Alemayehu T, Beyene T, Libman MD, et al. Prolonged empirical antibiotic therapy
- 455 is correlated with bloodstream infections and increased mortality in a tertiary care hospital in Ethiopia: bacteriology testing
- 456 matters. JAC-antimicrobial resistance. 2020;2(3):dlaa039.
- 457 25. Winsley TJ, Snape I, McKinlay J, Stark J, van Dorst JM, Ji M, et al. The ecological controls on the prevalence of
 458 candidate division TM7 in polar regions. Frontiers in microbiology. 2014;5:345.
- 26. CLSI. Performance Standards for Antimicrobial Susceptibility Testing.28th ed. CLSI guideline M100. Wayne, PA:
- 460 Clinical and Laboratory Standards Institute 2018.
- 461 27. CLSI. Performance Standards for Antimicrobial Susceptibility Testing.30th ed. CLSI guideline M100. Wayne, PA:
- 462 Clinical and Laboratory Standards Institute. 2020.
- 28. CLSI. Performance Standards for Antimicrobial Susceptibility Testing.31st ed. CLSI guideline M100. Wayne, PA:
 Clinical and Laboratory Standards Institute. 2021.
- CLSI. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Data; Approved Guideline-Fourth
 Edition. CLSI guideline M39-A4. Wayne, PA: Clinical and Laboratory Standards Institute. 2014.
- Li Z, Zhuang H, Wang G, Wang H, Dong Y. Prevalence, predictors, and mortality of bloodstream infections due to
 methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis. BMC
 infectious diseases. 2021;21(1):1-10.
- 470 31. Kłos M, Pomorska-Wesołowska M, Romaniszyn D, Wójkowska-Mach J, Chmielarczyk A. Antimicrobial Resistance
 471 in <i>Enterobacterales</i></i>
 472 Journal of Microbiology. 2021;2021:6687148.
- 473 32. Doern GV, Carroll KC, Diekema DJ, Garey KW, Rupp ME, Weinstein MP, et al. Practical Guidance for Clinical
- 474 Microbiology Laboratories: A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of
- 475 Methods for Addressing the Problem. Clinical Microbiology Reviews. 2019;33(1):e00009-19.


- 476 33. Chaplain D, Asutaku BB, Mona M, Bulafu D, Aruhomukama D. The need to improve antimicrobial susceptibility
- 477 testing capacity in Ugandan health facilities: insights from a surveillance primer. Antimicrobial Resistance & Infection
- 478 Control. 2022;11(1):1-7.
- 479
- 480



Significant Contaminants = No Bacterial Growth



S.aureus-Resistant



PEN-Penicillin, FOX-Cefoxitin, GEN-Gentamicin, CIP-Ciprofloxacin, CLI-Clindamycin, ERY-

Erythromycin, CHL-Chloramphenicol, TCY-Tetracycline